[Clinical results and problems of anti-androgen therapy of benign prostatic hypertrophy].
We evaluated the effect of anti-androgen therapy for benign prostatic hypertrophy. Patients showed a significant reduction in the prostatic weight measured by means of transrectal ultrasonography after 3 to 4 months of treatment. However, there were no patients who showed any symptomatic improvement despite a reduction in the prostatic weight. They had prostatic stones more frequently than the group who showed symptomatic improvement properly. We summarized some problems of anti-androgen therapy for benign prostatic hypertrophy.
Umeda
K
K
Department of Urology, School of Medicine, Toyama Medical and Pharmaceutical University.
D000284:Administration, Oral; D000368:Aged; D000500:Allylestrenol / Q000627:therapeutic use*; D000726:Androgen Antagonists / Q000627:therapeutic use*; D002715:Chlormadinone Acetate / Q000627:therapeutic use*; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D009277:Nandrolone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000473:pathology
D000726:Androgen Antagonists; D002715:Chlormadinone Acetate; D009277:Nandrolone; D000500:Allylestrenol; C005671:oxendolone